Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 3/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13570514 | 0.86 | F2 (0.53) | DPP4ERAP2ERAP1LNPEPF2 | |
| SCHEMBL31376320 | 0.86 | DPP4 (0.65) | DPP4ERAP2ERAP1LNPEPF2 | |
| SCHEMBL6980126 | 0.85 | AGTR2 (0.52) | DPP4 | |
| SCHEMBL28797928 | 0.80 | ERAP2 (0.48) | DPP4ERAP2ERAP1LNPEPF2 | |
| SCHEMBL3733552 | 0.80 | LMNA (0.52) | DPP4ERAP2ERAP1LNPEPACE | |
| SCHEMBL21067671 | 0.80 | FKBP1A (0.51) | OPRD1F2 | |
| SCHEMBL2176481 | 0.79 | KCNH2 (0.47) | DPP4ERAP2ERAP1LNPEPACE | |
| SCHEMBL13570391 | 0.79 | ERAP2 (0.45) | DPP4ERAP2ERAP1LNPEPF2 | |
| SCHEMBL27828766 | 0.79 | GAA (0.54) | DPP4ERAP2ERAP1LNPEPACE | |
| SCHEMBL17220302 | 0.79 | GAA (0.54) | DPP4ERAP2ERAP1LNPEPACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5714485-A | Piperidine and hexahydropyridazine thrombin inhibitors | MERCK & CO., INC. (US) | 1998-02-03 | — | — | US | disclosed |